The enzyme ACSL3 is strongly correlated with poor HCC prognosis, positioning it as a potential therapeutic target.<h4>Material and methods</h4>ACSL3 expression was assessed in vivo and ex vivo using comparative analysis. The gene discussed is ACSL3; the disease is hepatocellular carcinoma.